Media release –
New Findings Show Alcon Technologies Help Surgeons Improve Refractive Outcomes for Cataract Patients with Pre-Existing Astigmatism
Alcon, the global leader in eye care and a division of Novartis, presents new data that highlight the potential for its AcrySof® IQ Toric intraocular lenses (IOLs) and ORA System® to improve refractive outcomes for cataract patients with pre-existing astigmatism at the American Society of Cataract and Refractive Surgery (ASCRS) 2018 annual meeting taking place April 13-17 in Washington, D.C.
“At Alcon, our aspiration is that every patient with pre-existing astigmatism receive correction at the time of cataract surgery,” said Jim Di Filippo, Vice President and General Manager, US Surgical, Alcon. “That’s why we are proud to offer best-in-class products like AcrySof® IQ Toric IOLs and the ORA System® to help surgeons better manage astigmatism and achieve the best possible outcomes for patients.”
Findings of two new studies that demonstrate the value of Alcon products across a variety of real-world scenarios in astigmatism management will be shared during presentations at the ASCRS meeting:
AcrySof® IQ Toric IOL Demonstrates Superior Rotational Stability, Better Astigmatism Correction
A recently published study, “Comparing Rotational Stability of Two Toric IOLs,” shows that the Alcon AcrySof® IQ Toric IOL showed significantly greater rotational stability than the Tecnis® Toric IOL. The study aimed to compare the rotational stability of two commonly used astigmatism-correcting IOLs, and the primary outcome measure was the percentage of eyes with IOL rotation >5 and >10 degrees. The second main outcome was likelihood of requiring return to the operating room to reposition a rotated IOL. These results suggest that the AcrySof® IQ Toric IOLs are more effective at correcting astigmatism long term than the Tecnis® Toric IOL. The study will be presented by Dr. Bryan Lee at ASCRS on Sunday, April 15 from 8:12 – 8:17 a.m. at the Walter E. Washington Convention Center, Level 1, 143A.
New Findings Show Value of Alcon Technology in Improving Refractive Outcomes
Findings from “Analysis of an Intraoperative Aberrometry Database: Outcomes of a Toric IOL for Low Astigmatism,” a retrospective analysis for subjects implanted with the AcrySof® IQ Toric IOL, demonstrate that the Alcon ORA System®produces better refractive outcomes (lower spherical equivalent prediction error) than when a surgeon calculates the power of the IOL manually before surgery. These findings show the value of Alcon technologies in a real-world scenario and will be shared during a poster presentation by Drs. Robert Cionni and Michael Breen on Tuesday, April 17 from 10:17 – 10:22 a.m. at the Walter E. Washington Convention Center, Level 1, 144B.
Important Information About the Alcon Products Featured in this Alert
AcrySof®IQ Toric IOLs
AcrySof® IQ Toric IOLs are implanted in the eye of adult patients following cataract surgery, and are designed to correct pre-existing corneal astigmatism. This IOL corrects corneal astigmatism only when it is placed in the correct position in the eye. There is a possibility that the IOL could be placed incorrectly or could move within the eye. This may result in less improvement or a reduction in vision because your corneal astigmatism has not been fully corrected, or it may cause visual symptoms. The safety and effectiveness of AcrySof® IQ Toric IOLs has not been established in patients with certain eye conditions, such as glaucoma or diabetic retinopathy (an increase in eye pressure or complications of diabetes in the eye).
The ORA System® uses wavefront aberrometry data to measure and analyze the refractive power of the eye to support cataract surgical procedures. Preexisting retinal or corneal conditions may affect the accuracy of the measurements. Please refer to the ORA System® Operator’s Manual for a complete list of contraindications, warnings and precautions.
Additional important information about these products will be available at the Alcon booth #2617.
*Tecnis®is a registered trademark owned by or licensed to Abbott Medical Optics, Inc., its subsidiaries or affiliates.